Determination That Sutilains Ointment USP Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

摘要

The Food and Drug Administration (FDA) is announcing its determination that sutilains ointment USP (Travase Ointment) was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDA's) for sutilains ointment USP.